Updates are available Correction dated 2021-03-20
Click to view Correction: https://doi.org/10.1007/s00259-021-05321-3
-
Authors
Manson, G.
Brice, P.
Herbaux, C.
Silva, M. G.
Bouabdallah, K.
Deau, B.
Bouteloup, J.
Schiano, J. M.
Nicolas-Virelizier, E.
Maerevoet, M.
Ghesquieres, H.
Stamatoullas, A.
Antier, C.
Carlo-Stella, C.
de Charette, M.
Poizeau, F.
Dercle, L.
Houot, Roch
- License Information
-
More Information
Article History
Received: 29 June 2020
Accepted: 24 August 2020
First Online: 28 August 2020
Change Date: 20 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-021-05321-3
Compliance with ethical standards
:
: G.M. and P.B. have received consulting fees and/or honoraria from Bristol-Myers Squibb. M.G.S received research grant form Gilead Sciences, and was consultant for Abbvie, Gilead Sciences, Janssen Cilag, Roche. E.N-V. received consulting fees from Sanofi. A.S. has received consulting fees from Takeda and Celgene. C.C.-S. received honoraria for speaker engagements from Bristol Myers Squibb, Merck Sharp & Dohme, Amgen, Janssen Oncology, Astra-Zeneca; provided consultancy to Boehringer Ingelheim, Sanofi, ADC Therapeutics; and received scientific advisory fee from Servier, Novartis, Roche, ADC Therapeutics; and received research funding from Rhizen Pharmaceuticals. RH received honoraria from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. All other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
